Inflammatory pain sensitization is initiated by prostaglandin-induced phosphorylation of α3 glycine receptors (GlyRs) that are specifically located in inhibitory synapses on spinal pain sensory neurons.
INTRODUCTION
Members of the pentameric ligand-gated ion channel (pLGIC) receptor family mediate fast synaptic transmission in the nervous system. The cation-permeable nicotinic acetylcholine receptor (nAChR) is the most intensively studied member of this family, with other members including the anion-permeable glycine and GABA type-A receptors (GlyRs and GABA A Rs) and the cation-permeable serotonin type-3 receptor (5-HT 3 R) 1 . Functional pLGICs comprise an assembly of five homologous membrane-spanning subunits arranged symmetrically around a central pore. All subunits incorporate large N-terminal ligand-binding domains that form neurotransmitter-binding sites at the interface of adjacent domains. The eponymous extracellular Cys-loop is conserved among eukaryotic members of this family. In addition, GlyRs incorporate a second Cys-loop that forms the C loop ligand-binding domain that is crucial for glycine binding 2 . The ligand-binding domain is followed by four transmembrane α-helices, termed M1-M4, that each span the entire thickness of the cell membrane. Each subunit contributes an M2 domain to the lining of the axial water-filled pore. To facilitate comparison of pore-lining residues between different pLGIC members, a common M2 residue numbering system is used which assigns 1' and 19' to the innermost and outermost pore-lining residues, respectively. The M1, M2 and M3 domains are connected by short loops.
The intracellular domain linking M3 and M4 varies considerably in both length and amino acid sequence among different pLGIC subunits.
Although GlyRs are best known for mediating inhibitory neurotransmission in reflex circuits of the spinal cord, they also mediate inhibitory neurotransmission onto spinal nociceptive neurons in superficial laminae of the spinal cord dorsal horn. GlyR α3 subunits, which are otherwise sparsely distributed, are abundantly expressed in these synapses 3 . Chronic inflammatory pain sensitization is caused in part by a prostaglandin E 2 (PGE 2 )-mediated activation of protein kinase A (PKA), which in turn phosphorylates α3 GlyRs at S346, leading to a diminution of glycinergic synaptic current magnitude 3, 4 . This disinhibits spinal nociceptive sensory neurons resulting in chronic inflammatory pain sensitization. Due to their sparse distribution outside the spinal cord dorsal horn, α3 GlyRs have emerged as preferred therapeutic targets for chronic pain 5, 6 , and agents that potentiate α3 GlyRs have been shown to exhibit analgesic efficacy in animal models of chronic inflammatory pain 7 .
Our original aim was to compare glycine-induced conformational changes in α1 and α3 GlyRs in an attempt to identify structural differences that could be exploited in the design of α3-specific potentiators. To achieve this, we employed voltage-clamp fluorometry (VCF) to quantitate conformational changes occurring in the immediate vicinity of residues labeled with environmentally-sensitive fluorophores. Initially, we probed glycine-induced conformational changes at a fluorescent reporter attached at the external end (R271 or R19') of the M2 pore-lining domain. This revealed differences in glycine-induced conformations in α1
and α3 GlyRs that, to our surprise, were due to structural variations in their M3-M4 domains. This prompted us to investigate whether PKA-induced phosphorylation of S346 (in the α3 GlyR M3-M4 domain) may also produce extracellular conformational changes. Phosphorylation of S346 was found to induce conformational changes not only at the external end of M2, but also in the glycine-binding site.
RESULTS AND DISCUSSION
We employed VCF to compare glycine-induced conformational changes in α1 and α3 receptors in an attempt to identify structural differences that could be exploited in the design of α3-specific potentiators as analgesics. For these studies we employed the GlyR human α1 and rat α3L subunit cDNAs (Fig. S1 ) with
Uniprot accession numbers of P23415-2 (i.e., isoform b) and P24524, respectively. Both constructs incorporated the C41A mutation that eliminated the sole uncrosslinked extracellular sulfhydryl group. The C41A mutation has no effect on receptor function 8, 9 . Constructs incorporating only this mutation are termed wild type (WT). We initially compared the glycine-induced fluorescence responses of a methanethiosulfonate-rhodamine (MTSR) reporter covalently attached to R19'C in the α1 and α3 GlyRs.
Although the R19'C mutation impairs the glycine gating efficacy of the α1 GlyR 8-10 , we employed it here for two reasons, First, R19' forms part of the M2-M3 loop which is known to be intimately involved in receptor gating 11, 12 . Hence, if α1 and α3 GlyRs exhibit distinct quaternary structures, this difference should be reflected in their gating mechanisms and hence R19'C should be a promising location for detecting these.
Second, R19'C is the only known gating site that when fluorescently labeled gives a glycine-induced fluorescence change (ΔF) large enough to be quantitatively analysed 9 . The maximum glycine-induced fluorescence response (ΔF max ) in the MTSR-labeled α1-R19'C GlyR is about 20 % 9 . By comparison, application of a saturating (30 mM) glycine concentration to MTSR-labeled α3-R19'C GlyRs elicited a ∆F max of 5.1 ± 1.0 % (n = 13). As no detectable ∆F was ever observed in wild type (WT) MTSR-labeled α1-WT or α3-WT GlyRs (Table S1) , we conclude that the α3-R19'C GlyR is specifically labeled by MTSR.
A structural model of an α3 GlyR subunit displaying the location of R19' and the M2-M3 loop is presented in Fig. 1A . As previously observed for the α1-R19'C GlyR 9 , glycine current (ΔI) and ΔF dose-response relationships were almost overlapping in α3-R19'C GlyRs (Fig. 1B, C) . Indeed, using a paired t-test, the mean glycine ΔI half-maximal concentration (EC 50 ) of 1740 ± 270 µM (n = 13) was not significantly different from the mean glycine ΔF EC 50 of 1340 ± 210 µM (n = 13). However, both values were significantly larger than the corresponding α3-WT GlyR ΔI glycine EC 50 value (74 ± 2 µM, n = 6) using an unpaired t-test (P < 0.001 for both). Sample recordings of ΔF max responses from MTSR-labeled α3-R19'C GlyRs suggested that they were smaller in magnitude and slower to decay to baseline than those recorded from MTSR-labeled α1-R19'C GlyRs (Fig. 1D) . Averaged results confirmed that ΔF max responses from α3-R19'C GlyRs were significantly reduced in magnitude, although their saturating current magnitude (ΔI max ) values were not significantly different (P > 0.08 by unpaired t-test) (Fig. 1E) . We quantified ΔF decay rates by determining the ratio of the ΔF max half-decay time to the ΔI max half-decay time in the same oocyte to control for possible differences in ΔI max decay rate between receptor subtypes. As shown in Fig. 1F , ΔF max did indeed decay at a significantly slower rate in MTSR-labeled α3-R19'C GlyRs relative to MTSR-labeled α1-R19'C GlyRs. These differences were surprising because the amino acid sequences of α1 and α3 subunits are identical in all domains that are likely to come into contact with a rhodamine attached at the 19'C position.
Due to this unexpected finding, we compared the effects of a variety of pharmacological modulators on ΔF max responses of MTSR-labeled α1-R19'C and α3-R19'C GlyRs. Although taurine and β-alanine are both very low efficacy agonists of α3-R19'C GlyRs, they elicit disproportionately large ΔF increases 9 . Consistent with this, although saturating taurine evoked no ∆I in α3-R19'C GlyRs (Fig. S2A) , it evoked mean ΔF max near 25 % of that produced by a saturating glycine concentration (Fig. S2B , Table S1 ). Similarly, saturating β-alanine evoked a very small ΔI max but a large ∆F max that was ~50 % of that produced by saturating glycine (Fig. S2A and B, Table S1 ). To facilitate comparison with glycine-mediated responses, Fig. S1B shows mean ∆I and ∆F concentration-response relationships for glycine, β-alanine and taurine with all averaged ΔI max , ΔF max , EC 50 and Hill coefficient (n H ) values summarized in Table S1 . All variables corresponded closely to those recorded from MTSR-labeled α1-R19'C GlyRs under similar experimental conditions 9 .
Ivermectin, which irreversibly activates α1 and α3 GlyRs 13, 14 , was previously shown to activate MTSRlabeled α1-R19'C GlyRs without inducing a detectable ΔF 9 . Here we found that saturating (15 µM)
ivermectin evoked slowly activating currents in MTSR-labeled α3-R19'C GlyRs although detectable ΔF was observed (Fig. S2C ).
Finally, we compared the effects of the allosteric inhibitor, picrotoxin, and the classical competitive antagonist, strychnine. When applied alone, picrotoxin did not evoke significant ∆I or ∆F changes in oocytes expressing MTSR labeled α3-R19'C GlyRs (Fig. S2D) . However, when co-applied with EC 50 glycine, 50
µM picrotoxin potently inhibited the current, although the ∆F increased significantly (17.3 ± 2.7 %, n=6).
Strychnine also had no effect when applied alone, but significantly reduced ΔF by 48.7 ± 7.6 % (n=6) when co-applied with EC 50 glycine (Fig. S2E ). The effects of both drugs on the direction of ΔF responses are consistent with those observed at MTSR-labeled α1-R19'C GlyRs 9 . From all these results, we infer that rhodamine labels attached to α1-R19'C and α3-R19'C GlyRs respond similarly to a variety of pharmacological manipulations, with the main difference being that α3-R19'C GlyRs exhibit smaller glycine-induced ΔF max values and slower ΔF decay rates.
To isolate the domain responsible for the differential ΔF response characteristics, we initially generated a series of six chimeras, labeled Chi1-Chi6 as shown in Fig. 2A . Each chimera was constructed from three variable modules: a ligand-binding domain, an M1-M3 transmembrane bundle plus large intracellular M3-M4 domain, and an M4 plus short C-terminal tail. A cysteine was introduced at the R19'C position of each chimera. The cDNAs for all chimeras were subcloned into the pGEMHE oocyte expression vector and functionally expressed in oocytes. Glycine ΔI and ΔF dose-response relationships were measured for all six chimeras and all mean glycine EC 50 , n H , ΔI max and ΔF max values are summarized in Table S2 . Mean ΔI max values were similar for all six chimeras (Fig. 2B) . However, the ΔF/ΔI half-decay time ratios and ∆F max values of three chimeras (Chi3, Chi5, Chi6) were all similar to those of α1-R19'C GlyRs whereas those of the other three chimeras (Chi1, Chi2, Chi4) were significantly different from α1-R19'C GlyRs but similar to those of α3-R19'C GlyRs (Fig. 2C, D) . These results indicate that the differences in ΔF response characteristics can be transposed from the α1 to the α3 GlyR (and vice versa) by transposing the M1-M3 transmembrane bundle plus M3-M4 domain.
The M1-M3 transmembrane bundle amino acid sequences are very highly conserved between α1 and α3
GlyRs, with nonconserved residues existing only at I240 and G254 of the α1 subunit (residue numbering is the same for both subunits). The corresponding residues in the α3 GlyR are valine and alanine. To determine whether either of these was responsible for the differential ΔF response, we investigated the α1-R19'C-I240V, α1-R19'C-G254A, α3-R19'C-V240I and α3-R19'C-A254G double mutant GlyRs. However, as these mutations produced no significant change in ΔF properties, we generated another two chimeras (ChiA and ChiB, Fig. 2A ) where only the M3-M4 domains were exchanged. The mean glycine EC 50 , n H , ΔI max and
ΔF max values for ChiA and ChiB receptors, measured both before and after MTSR-labeling, are summarized in Table S2 . Mean ΔI max and ΔF max responses of both chimeras, plus those of the original α1-R19'C and α3-R19'C GlyRs, are shown in Fig. 2B and C. The ΔI max of labeled ChiA was significantly reduced relative to those of both α1-R19'C and α3-R19'C GlyRs, possibly implying impaired surface expression. Nevertheless, the results for ChiB unequivocally indicate that transposing the M3-M4 domain from the α1-R19'C into the α3-R19'C GlyR produces an increased ΔF max similar to that of the α1-R19'C GlyR (Fig. 2 C,D) . Similarly, analysis of the ΔF/ΔI half-decay time ratios indicated that this value can also be transferred between receptors by transferring their M3-M4 domains (Fig. 2D ). Thus, these results indicate that the primary structure of the M3-M4 domain influences tertiary structure in the immediate vicinity of a rhodamine label attached to R19'C (Fig. 1A ).
We next hypothesized that dynamic changes in M3-M4 loop conformation may also influence receptor conformation near R19'C. A PKA phosphorylation site has been identified at S346 in the α3 GlyR M3-M4 domain 3 . To determine whether phosphorylation of this site alters the microenvironment of a rhodamine attached to α3-R19'C, we investigated the effects of two mutations to this residue: S346G to eliminate the PKA site and S346E to mimic phosphorylation. The mean glycine EC 50 , n H , ΔI max and ΔF max values for the unlabeled and MTSR-labeled α3-R19'C-S346E and α3-R19'C-S346G double mutant GlyRs are summarized in Table S2 . The mean ΔI max and ΔF max values presented in Fig. 3A indicate that ΔI max was not significantly affected by either mutation, suggesting no effect on surface expression levels. However, the mean ΔF max was significantly reduced in α3-R19'C-S346E GlyRs (Fig. 3A) . Moreover, the ΔF/ΔI half-decay time ratio was significantly faster in the α3-R19'C-S346G GlyR than in the α3-R19'C or α3-R19'C-S346E GlyRs (Fig.   3B ). Thus, the phosphorylation-mimicking S346E mutation shifted both ΔF characteristics (i.e., peak magnitude and decay rate) from α1-like to α3-like, whereas eliminating the site (i.e., S346G) produced the reverse trend. From this result, we hypothesized that phosphorylation should reduce ΔF max and possibly also prolong the ΔF half-decay time in MTSR-labeled α3-R19'C GlyRs.
We tested this directly by treating α3-R19'C GlyRs with 20 µM forskolin for 15 min to phosphorylate S346. As shown in the sample recording in Fig. 3C , forskolin reversibly inhibited the ΔF induced by EC 50 glycine in α3-R19'C GlyRs. A control experiment revealed that forskolin produced no significant change in ΔF magnitude in phosphorylation-deficient α3-R19'C-S346G GlyRs (Fig. 3D) , ruling out the possibility of non-specific forskolin effects on ΔF. Similarly, application of 20 µM forskolin to α1-R19'C GlyRs produced percentage changes in ΔI max and ΔF max of 105 ± 8 % and 95 ± 11 % (both n = 20), neither of which was significant using a paired t-test (P > 0.1 for both). A control dimethyl sulfoxide application to α3-R19'C GlyRs revealed that the incomplete recovery of the ΔF response following forskolin treatment was either a time-or solvent-dependent effect (Fig. 3E, left) , most likely representing fluorophore bleaching. As the EC 50 glycine ΔI magnitude remained constant throughout each experiment ( Fig. 3C -E), we can rule out an effect of phosphorylation on GlyR surface expression levels or glycine sensitivity. Averaged results shown in Fig. 3E (center and right panels) confirmed that forskolin inhibited the ΔF response of α3-R19'C GlyRs by ~50 %, but had no effect on α3-R19'C-S346G GlyRs. Together, these results indicate that phosphorylation of S346 induced a conformational change in the immediate vicinity of the rhodamine attached to R19'C in the α3 GlyR. The direction of this ΔF change is in accordance with that elicited by the phosphorylationmimicking S346E mutation.
As phosphorylation induces a conformation change in or around the M2-M3 loop, we hypothesized that it may induce a global conformational change that propagates to the glycine-binding site. To test this, we investigated the effects of forskolin on glycine-and strychnine-induced ΔF responses in α3-N203C GlyRs that had been labeled by the sulfhydryl-reactive 2-((5(6)-tetramethylrhodamine)carboxylamino)ethyl methanethiosulfonate (MTS-TAMRA). There were three reasons for choosing this site. First, N203 lies at the 'tip' of the loop C glycine-binding domain (Fig. 1A ) that is thought to close around the agonist as it binds in its subunit interface pocket [15] [16] [17] . Second, MTS-TAMRA-labeled α1-N203C GlyRs elicit large ΔFs (>40 %)
in response to the binding of either glycine or strychnine 18 . Third, unlike R19'C, the N203C mutation does not affect glycine sensitivity 18 . We first quantified the glycine ΔI and ΔF dose-response relationships in unlabeled and MTS-TAMRA-labeled α3-N203C and α3-N203C-S346G GlyRs, with all mean glycine EC 50 , n H , ΔI max and ΔF max values summarized in Table S3 . Both mutants exhibited similar ΔI max values which were not affected by MTS-TAMRA labeling. However, ΔF max values were significantly larger in labeled α3-N203C-S346G GlyRs than in labeled α3-N203C GlyRs (7.1 ± 0.5 vs 4.0 ± 0.4 %, p < 0.05 by unpaired ttest, n=5 oocytes each). The ΔF max values induced by saturating (10 µM) strychnine were also significantly larger in α3-N203C-S346G GlyRs (8.4 ± 0.2 vs 5.4 ± 0.3 %, p < 0.001 by unpaired t-test, n=5 oocytes each).
To determine whether phosphorylation induces a conformational change in the vicinity of a label attached to N203C, we tested the effects of a 15 min application of 20 µM forskolin on MTS-TAMRA-labeled α3-N203C and α3-N203C-S346G GlyRs. As shown in Fig. 4A and B, forskolin reversibly reduced both glycine-and strychnine-mediated ΔF max responses in labeled α3-N203C GlyRs. Non-specific effects were eliminated on the grounds that forskolin had no significant effect on strychnine-mediated ΔF max responses in α3-N203C-S346G GlyRs (Fig. 4C ). Forskolin did, however, have a small but statistically significant effect on glycine-mediated ΔF max responses in α3-N203C-S346G GlyRs (Fig. 4C, right) . We thus infer that phosphorylation of S346 induces a conformational change in or near the α3 GlyR glycine-binding site.
We next investigated whether the rhodamine attached to N203C could detect molecular changes occurring within the glycine-binding pocket. For this we employed two β-carboline derivatives, harmane and 6-methoxyharmalan, that differ in structure only by a methyoxy group at the C6 position (Fig. S3A) . These compounds, which are competitive antagonists of glycine, are predicted to bind in the glycine-binding site pocket in almost identical orientations 19 . Saturating (200 µM) concentrations of both β-carbolines elicited ΔF decreases in MTS-TAMRA-labeled α3-N203C GlyRs (Fig. S3B) , with the average ΔF max induced by 6-methoxyharmalan being significantly larger than that induced by harmane (-3.7 ± 0.4 vs -1.0 ± 0.04 %, p < 0.05 by unpaired t-test, n=5 oocytes each). Moreover, forskolin treatment inhibited the 6-methoxyharmalanmediated ΔF max , although it had no effect on that produced by harmane (Fig. S3B, D) . Differential responses were also observed in α3-N203C-S346G GlyRs, with 6-methyoxyharmalan and harmane eliciting ΔF max values of -4.5 ± 0.5 and +0.6 ± 0.1 %, respectively (P < 0.05 by unpaired t-test, n = 5 oocytes each). As expected, forskolin elicited either insignificant, or small but significant, effects on the ΔF max responses elicited by either compound in phosphorylation-deficient α3-N203C-S346G GlyRs (Fig. S3C, D) . These data indicate that a fluorophore attached to N203C successfully reports the addition of a small methoxy moiety into the glycine-binding pocket.
We then applied the same procedure to investigate the competitive antagonist, tropisetron, which is structurally unrelated to the β-carbolines (Fig. S3A ) but also binds in the glycine-binding pocket 20, 21 . In the MTS-TAMRA-labeled α3-N203C and α3-N203C-S346G GlyRs, saturating (1 mM) tropisetron induced mean ΔF max responses of +3.3 ± 0.3 and +7.3 ± 0.5 %, respectively (P < 0.05 by unpaired t-test, n = 5 oocytes each). As shown in Fig. S3B -E, phosphorylation also reduced the tropisetron-induced ΔF max response in α3-N203C GlyRs.
The above results are consistent with phosphorylation inducing a conformational change in or near the glycine-binding pocket. To determine whether it produces a conformational change inside the pocket, we quantified the effect of phosphorylation on the efficacy with which tropisetron, 6-methoxyharmalan and harmane inhibited EC 20 (40 µM) glycine-activated ΔIs in α3-WT GlyRs. This experiment also avoids the use of chemically modified receptors. As shown in Fig. 5A and B, the potency with which 150 µM tropisetron and 100 µM 6-methoxyharmalan inhibited α3-WT GlyRs was significantly and reversibly enhanced by phosphorylation. In contrast, the inhibition produced by 60 µM harmane was not affected by phosphorylation. Consistent with results from the α3-R19'C and α3-N203C GlyRs described above (Fig. 3E,   4C ), glycine-gated ΔIs in α3-WT GlyRs were not affected by phosphorylation. Thus, the results strongly suggest that phosphorylation induces a conformational change in the glycine-binding site.
Given that S346 phosphorylation inhibits α3-WT GlyRs expressed in mammalian HEK293 cells 3, 7 but not in Xenopus oocytes, it is evident that this effect is expression system-specific. It was therefore relevant to determine whether phosphorylation also induces a conformational change in the glycine-binding site of HEK293 cell-expressed α3-WT GlyRs. As it is not feasible to perform VCF experiments on HEK293 cells due to the high level of non-specific fluorophore labelling, we employed a pharmacological approach only.
Specifically, we continually monitored the inhibitory potency of a 20 µM (~IC 50 ) concentration of tropisetron on EC 50 (180 µM) glycine-activated ΔIs before, during and after forskolin treatment. Fig. 6A shows a typical recording, together with expanded sections of the traces recorded before and immediately after forskolin exposure. It shows that forskolin simultaneously reduced ΔI magnitude and enhanced tropisetron potency.
Results averaged from 6 cells confirm both effects and demonstrate their reversibility after a 15 min wash (Fig. 6B, C) . In contrast, when applied to α1-WT GlyRs, forskolin was never observed to elicit a detectable response (defined as a >10 % change in current over a 10 min application period) in each of 10 cells in which it was examined. As tropisetron is a competitive antagonist, it is possible that its enhanced potency in could be due to a phosphorylation-mediated reduction in glycine affinity in HEK293 cells. We tested this directly by applying alternating EC 50 (180 µM) and EC 100 (1 mM) concentrations of glycine to α3-WT GlyRs before, during and after the period of forskolin exposure (Fig. 6D ). As forskolin inhibited EC 100 currents to a significantly greater extent than it inhibited EC 50 currents (Fig. 6E) , it is evident that glycine sensitivity is actually enhanced by phosphorylation. This allows us to conclude that phosphorylation directly alters tropisetron potency in α3-WT GlyRs.
The main insight of this study is that PKA-dependent phosphorylation of α3 GlyRs produces a conformational change that propagates to the glycine-binding site. Three main lines of evidence support our conclusion that phosphorylation has indeed taken place. First, forskolin is well known to stimulate cAMP accumulation and thus activate PKA in HEK293 cells. Second, the effect of forskolin on ΔF magnitude in the α3-R19'C GlyR was similar to that of the phosphorylation-mimicking mutation, S346E (Fig. 3A, C) .
Third, forskolin had no effect on ΔF responses in phosphorylation-deficient α3-R19'C-S346G GlyRs or on α1-R19'C GlyRs that do not contain an endogenous PKA phosphorylation site.
The present study demonstrates two separable effects of phosphorylation on α3 GlyRs. The first effect, observed only in HEK293 cell-expressed receptors, is the reduced current magnitude. The fact that we observed no effect of phosphorylation on α3 GlyR current magnitudes in Xenopus oocytes was fortuitous because it allowed us to eliminate receptor internalization or changes in GlyR open probability as possible explanations for our VCF results. Thus, it permitted us to unequivocally conclude that phosphorylation of S346 exerts a global conformational change that propagates to the α3 GlyR glycine-binding site.
The second effect of phosphorylation, observed in both the HEK293 cell and Xenopus oocyte expression systems, is the change in structure at the glycine-binding site. The main lines of evidence in support of this are, 1) a phosphorylation-mediated micro-environmental change at a fluorophore attached to loop C of the glycine-binding site, and 2) a phosphorylation-mediated enhancement of the inhibitory potency of tropisetron. The magnitude of this potency increase was remarkably similar in the oocyte and HEK293 cell expression systems. Phosphorylation also enhanced receptor sensitivity to glycine in HEK293 cells (Fig. 6E) , possibly via a similar mechanism.
We speculate that the differential effect of phosphorylation in the two expression systems may be due to differences in the expression levels of one or more intracellular signaling molecules. We propose that S346 phosphorylation, in addition to directly altering glycine-binding site structure, either exposes or occludes a binding site for an expression system-specific intracellular signaling molecule. The subsequent alteration in binding of this molecule to the α3 GlyR thus results in a glycine current magnitude change in HEK293 cells only. The identification of this putative signaling molecule may reveal new therapeutic targets for chronic pain.
It has previously been shown that phosphorylation by PKA or PKC results in the internalization of both recombinant α1 and native neuronal GlyRs 27, 28 . We cannot rule internalization out as a possible explanation for the PKA-dependent inhibition of α3 GlyRs we describe in HEK293 cells. We also note that S337, S349
and S380 in the M3-M4 domain of the rat α3L GlyR are also strong phosphorylation consensus sites (Fig.   S1 ). Although it is possible they may also contribute to the effects of PKA-dependent phosphorylation, they
were not investigated here given that ablation of the S346 phosphorylation site completely eliminated the effects of phosphorylation on α3 GlyR current magnitude 3 .
There is abundant evidence for phosphorylation-induced conformational changes in pLGICs. 5, 6 . Selective enhancement of α3 GlyRs should therefore produce analgesia, and recent evidence indicates that potentiators specific for α3 GlyRs are indeed analgesic in animal models of chronic inflammatory and neuropathic pain 7 . Our finding that the α3 GlyR glycine-binding site is forced into a unique configuration in chronic pain implies that it should be possible to design drugs to selectively potentiate phosphorylated α3 GlyRs, potentially providing a more precisely targeted analgesic therapy. Furthermore, serotonin-1A receptor activation dephosphorylates S346 in α3 GlyRs in brainstem respiratory neurons, thereby increasing glycinergic synaptic current magnitude and counteracting opioidinduced breathing depression 33 . This implies that drugs that selectively potentiate phosphorylated α3 GlyRs may also be efficacious as treatments for opioid-induced breathing disorders.
In conclusion, we have demonstrated that structural changes in the M3-M4 domain can impact on the conformation of the extracellular domains of a pLGIC receptor. In particular, we have shown that phosphorylation of S346 exerts a global conformational change that propagates to the α3 GlyR glycinebinding site. This finding is important for two reasons. First, it provides the first direct evidence for phosphorylation producing extracellular conformational changes in any pLGIC, and thus provides a new locus for investigating how phosphorylation modulates the structure and function of these receptors. Second, it shows that chronic inflammatory pain is accompanied by a unique conformational change in the α3 GlyR glycine-binding site, which raises the possibility of developing analgesic drugs to specifically target diseaseaffected receptors.
MATERIALS AND METHODS
Chemicals: MTSR and TAMRA were obtained from Toronto Research Chemicals. Glycine, β-alanine, taurine, ivermectin, picrotoxin, strychnine, forskolin, tropisetron, harmane and 6-methoxyharmalan were all obtained from Sigma. Glycine, β-alanine, taurine and strychnine were dissolved in water. All other drugs were prepared as 20-100 mM stocks in dimethylsulfoxide and kept frozen at -20 o C. From these stocks, solutions for experiments were prepared on the day of recording.
Molecular biology:
Plasmid DNAs for the human α1 and rat α3L GlyR subunits were kindly provided by Prof. Peter Schofield (Neuroscience Research Australia) and Prof. Robert Harvey (University College, London), respectively. For Xenopus oocyte recordings, the subunit DNAs were subcloned into pGEMHE, a plasmid vector optimized for oocyte expression. The α1 and α3L constructs both incorporated the C41A mutation that eliminated the sole uncrosslinked extracellular sulfhydryl group. Site directed mutagenesis was performed using the QuikChange mutagenesis kit (Stratagene). Successful incorporation of the mutations was confirmed through automated sequencing of the entire cDNA coding region. Chimeras were constructed using a multiple-template-based sequential PCR protocol as recently described 34 . The join sites between the α1 and α3 sequences used to create chimeras Chi1 -Chi6 were located between the following pairs of residues: α1 Y223/L224 and α3 Y223/L224 for the N terminal end of M1, and α1 R392/I393 and α3 R400/A401 for the C terminal end of the M3-M4 loop (Fig. S1 ). ChiA involved inserting the α3 GlyR residues K322 -R400, inclusive, in place of α1 GlyR residues R322 -R392, inclusive. ChiB incorporated the reverse domain substitution.
Ten micrograms of each cDNA was linearized by NheI or PstI and then purified by PCR-purification kit (Qiagen). The capped RNAs were transcribed from cDNA using the Ambion T7 mMessage mMachine kit, purified by RNAMinikit (Qiagen) eluted with DNA/RNAase free water and diluted to 200ng/µl for oocyte injection.
Oocyte preparation, injection and labeling: Female Xenopus laevis frogs (Xenopus Express) were anaesthetized with 5mM MS-222 (Sigma Aldrich) and stage VI oocytes were removed from ovaries and washed thoroughly in OR-2 (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 5 mM HEPES, pH 7.4). The oocytes were then incubated in collagenase (Sigma Aldrich) in OR-2 for 2 hr at room temperature, rinsed and stored in OR-2 at 18 °C.
All oocytes were injected with 10 ng of mRNA into the cytosol. To achieve the high levels of expression required for the detection of the fluorescent signal over the background (due to oocyte autofluorescence and non-specific binding of the dye) the oocytes were incubated at 18 °C for 3-10 days after injection. The incubation solution contained 96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM HEPES, 0.6 mM theophylline, 2.5 mM pyruvic acid, 50 μg/ml gentamycin (Cambrex Corporation) and 5 % horse serum (Hycell), at pH 7.4.
On the day of recording, the oocytes were transferred into ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM HEPES, pH 7.4) and stored on ice. To label with either MTSR or MTS-TAMRA, oocytes were transferred into the labeling solution containing 10 μM of either compound in ND96 for 25 s.
The oocytes were then washed and stored in ND96 for up to 6 hours before recording. All labeling steps were performed on ice.
VCF:
We employed an inverted microscope (Eclipse TE300, Nikon Instruments) equipped with a high-Q tetramethylrhodamine isothiocyanate filter set (Chroma Technology), a Plan Fluor 40x objective (Nikon Instruments) and an H7360-03 photomultiplier detection system (Hamamatsu Photonics) attached to the side port of the microscope. An excitation filter wheel including a shutter and an emission filter wheel were controlled through a Lambda 10-2 unit (Sutter Instruments). A Lambda LS 175-Watt xenon arc lamp served as a light source and was coupled to the microscope via a liquid light guide (Sutter Instruments). The design of the custom made recording chamber has been described previously 35 . An automated perfusion system 
HEK293 cell culture:
We employed HEK293 cell lines that stably expressed either α1 or α3L GlyRs.
Generation of these cell lines has previously been described 36 . Cells were cultured on glass coverslips in Dulbecco's modified Eagle Medium supplemented with G-418 (1 mg/ml), penicillin (100 U/ml), streptomycin (100 mg/ml) and 10 % Serum Supreme and maintained at 37 ºC in a 5 % CO 2 incubator. 
Patch clamp electrophysiology:
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The authors declare no competing financial interest. Table S1 . D. Sample recordings from α1-R19'C and α3-R19'C GlyRs showing typical differences in the magnitude and decay rates of ΔF max responses. E. Comparison of averaged ΔI max and ΔF max values. F. Comparison of ΔF max decay rates. In this analysis, the ΔF max half-decay times were ratioed with the corresponding ΔI max half-decay times to normalize for possible differences in ΔI decay rate between α1 and α3 GlyRs. *** p < 0.001 compared to the α1-R19'C GlyR by unpaired t-test. The fractional increase in inhibition after phosphorylation is indicated by a corresponding reduction in the percentage current. * p < 0.05, ** p < 0.01 relative to control using paired t-test. There was no significant difference among the EC 50 , n H or ΔI max data using one way ANOVA followed by Dunnett's post hoc test. A statistical analysis of ΔF max and ΔF/ΔI half decay ratio data is presented in Fig. 3 . Fig. S1 . Amino acid sequence alignment of the coding region of the human α1 GlyR subunit (Uniprot accession number: P23415-2, isoform b) and the rat α3L GlyR subunit (Uniprot accession number: P24524). The alignment was generated using ClustalW. The residues that were mutated in this study are shown in blue. In addition to S346, the residues shown in red are also predicted to be serine phosphorylation sites according to the NetPhos 2.0 Server. Orange vertical lines denote the locations of subunit join sites used in creating α1−α3 chimeras.
